pharmaceuticals
03.07.2017
R.Petrosyan: participation of foreign companies in the efforts for government orders is a pledge of international competitiveness of Russian suppliersmore![R.Petrosyan: participation of foreign companies in the efforts for government orders is a pledge of international competitiveness of Russian suppliers](/assets/components/gallery/connector.php?action=web/phpthumb&ctx=web&w=123&h=123&zc=1&far=C&q=90&src=/upload/news/Без имени.jpg)
Preferences such as denial of access of foreign companies to government orders hamper development of Russian market and unreasonably increase budgetary expenses
more
28.06.2017
Timophey Nizhegorodtsev: drug price-setting should be based on the indicative method more
Experts supported FAS proposals on new methods for registering and reregistering the ceiling ex-works prices for the drugs included in the list of vital and essential drugs
more
28.06.2017
Substitutability of Hepatitis C drugs, established by FAS, saved more than 18 million RUB to the budgetmore![Substitutability of Hepatitis C drugs, established by FAS, saved more than 18 million RUB to the budget](/assets/components/gallery/connector.php?action=web/phpthumb&ctx=web&w=123&h=123&zc=1&far=C&q=90&src=/upload/news/lori-0003862793-bigwww (1).jpg)
FAS sent explanations to the Ministry of Health Care of the Russian Federation on preparing documents for procurement of medicinal drugs with the “Cepeginterferon alpha-2b” and “Peginterferon alpha-2b” International Non-Proprietary Names (INN)
more
19.06.2017
4 bid-rigging cases for supplies of medicinal drug and medical products are consolidatedmore![4 bid-rigging cases for supplies of medicinal drug and medical products are consolidated](/assets/components/gallery/connector.php?action=web/phpthumb&ctx=web&w=123&h=123&zc=1&far=C&q=90&src=/upload/news/lori-0002600700-smallwww.jpg)
21 entities and the Office of the Head of the Republic of Khakassia are brought in as respondents to the bid-rigging cases for supplies of medicinal drugs and medical products
more
![FAS: the health system is not ready for the risk-sharing drug supply systems](/assets/components/gallery/connector.php?action=web/phpthumb&ctx=web&w=123&h=123&zc=1&far=C&q=90&src=/upload/news/lori-0005868896-bigwww_slider.jpg)
The national health care system requires drastic changes in terms of clinical recommendations, interactions between medical doctors and pharmaceutical companies as well as creating a uniform system of implementing and objective evaluation of the efficiency of medicinal drugs under a risk-sharing model
more